Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 2
1958 3
1963 13
1964 32
1965 7
1968 1
1972 1
1976 2
1984 2
1985 1
1990 2
1992 3
1993 4
1994 7
1995 2
1996 8
1997 3
1998 5
1999 10
2000 9
2001 9
2002 23
2003 9
2004 13
2005 20
2006 22
2007 18
2008 23
2009 11
2010 13
2011 21
2012 17
2013 24
2014 36
2015 47
2016 43
2017 46
2018 42
2019 54
2020 60
2021 66
2022 56
2023 67
2024 67
2025 75
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

901 results

Results by year

Filters applied: . Clear all
Page 1
Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
Honig LS, Sabbagh MN, van Dyck CH, Sperling RA, Hersch S, Matta A, Giorgi L, Gee M, Kanekiyo M, Li D, Purcell D, Dhadda S, Irizarry M, Kramer L. Honig LS, et al. Alzheimers Res Ther. 2024 May 10;16(1):105. doi: 10.1186/s13195-024-01441-8. Alzheimers Res Ther. 2024. PMID: 38730496 Free PMC article. Clinical Trial.
There were 9 deaths during the OLE, with 4 deemed possibly related to study treatment. Of the 24 deaths in Core + OLE, 3 were due to intracerebral hemorrhage (ICH): 1 placebo in the Core due to ICH, and 2 lecanemab in OLE with concurrent ICH (1 on tissue plas …
There were 9 deaths during the OLE, with 4 deemed possibly related to study treatment. Of the 24 deaths in Core + OLE, 3 were …
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
O'Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH, López JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Sabatine MS. O'Donoghue ML, et al. Circulation. 2022 Oct 11;146(15):1109-1119. doi: 10.1161/CIRCULATIONAHA.122.061620. Epub 2022 Aug 29. Circulation. 2022. PMID: 36031810 Clinical Trial.
RESULTS: A total of 6635 patients were enrolled in FOURIER-OLE (3355 randomized to evolocumab and 3280 to placebo in the parent study). Median follow-up in FOURIER-OLE was 5.0 years; maximum exposure to evolocumab in parent plus FOURIER-OLE was 8.4 years. At …
RESULTS: A total of 6635 patients were enrolled in FOURIER-OLE (3355 randomized to evolocumab and 3280 to placebo in the parent study …
Ole e 3, a Candidate for in vivo Diagnosis of Polcalcin Sensitization.
Moya R, González-Ruiz A, Beitia JM, Carnés J, López-Matas MÁ. Moya R, et al. Int Arch Allergy Immunol. 2021;182(6):465-473. doi: 10.1159/000512303. Epub 2021 Jan 18. Int Arch Allergy Immunol. 2021. PMID: 33461195
Ole e 3 enabled diagnosis of polcalcin-sensitized patients, and a good correlation was revealed with ImmunoCAP. A 50% inhibition in IgE binding was obtained with 2.8 ng of Ole e 3 for rBet v 4 and 3.9 ng for rPhl p 7. DISCUSSION/CONCLUSION: Native O …
Ole e 3 enabled diagnosis of polcalcin-sensitized patients, and a good correlation was revealed with ImmunoCAP. A 50% inhibiti …
Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.
Gaba P, O'Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, Im K, Murphy SA, De Ferrari GM, Gaciong ZA, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Flores-Arredondo JH, López JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Giugliano RP, Sabatine MS. Gaba P, et al. Circulation. 2023 Apr 18;147(16):1192-1203. doi: 10.1161/CIRCULATIONAHA.122.063399. Epub 2023 Feb 13. Circulation. 2023. PMID: 36779348 Clinical Trial.
We also performed sensitivity analyses evaluating cardiovascular and safety outcomes in the entire FOURIER and FOURIER-OLE patient population. Multivariable modeling was used to adjust for baseline factors associated with achieved LDL-C levels. RESULTS: In FOURIER-OLE …
We also performed sensitivity analyses evaluating cardiovascular and safety outcomes in the entire FOURIER and FOURIER-OLE patient po …
Ole e 15 and its human counterpart -PPIA- chimeras reveal an heterogeneous IgE response in olive pollen allergic patients.
San Segundo-Acosta P, Oeo-Santos C, Navas A, Jurado A, Villalba M, Barderas R. San Segundo-Acosta P, et al. Sci Rep. 2019 Oct 21;9(1):15027. doi: 10.1038/s41598-019-51005-2. Sci Rep. 2019. PMID: 31636292 Free PMC article.
Here, the amino acid differences between Ole e 15 and its weak cross-reactive human homolog PPIA were grafted onto Ole e 15 to assess the contribution of specific surface areas to the IgE-binding. Eight Ole e 15-PPIA chimeras were produce …
Here, the amino acid differences between Ole e 15 and its weak cross-reactive human homolog PPIA were grafted onto Ole …
The allergenic relevance of profilin (Ole e 2) from Olea europaea pollen.
Martínez A, Asturias JA, Monteseirín J, Moreno V, García-Cubillana A, Hernández M, de la Calle A, Sánchez-Hernández C, Pérez-Formoso JL, Conde J. Martínez A, et al. Allergy. 2002;57 Suppl 71:17-23. doi: 10.1034/j.1398-9995.2002.057s71017.x. Allergy. 2002. PMID: 12173264 Review.
Olive pollen extracts also contain a profilin allergen (Ole e 2). This protein has been characterized in detail, so the amino-acid sequence of three isoforms and the structural model of one of them are already known. The prevalence of Ole e 2 for olive …
Olive pollen extracts also contain a profilin allergen (Ole e 2). This protein has been characterized in detail, so the amino- …
Epithelial Permeability to Ole e 1 Is More Dependent on the Functional State of the Bronchial Epithelium Than on the Activity of Der p 1 Protease Acting as an Adjuvant to the Bystander Allergen.
López-Rodríguez JC, González M, Bogas G, Mayorga C, Villalba M, Batanero E. López-Rodríguez JC, et al. J Investig Allergol Clin Immunol. 2021 Jul 26;31(4):343-346. doi: 10.18176/jiaci.0603. Epub 2020 Oct 8. J Investig Allergol Clin Immunol. 2021. PMID: 33030433 Free article. No abstract available.
Secondary Outcomes of the Ole e 1 Proteins Involved in Pollen Tube Development: Impact on Allergies.
Fernández-González M, González-Fernández E, Fernández-González D, Rodríguez-Rajo FJ. Fernández-González M, et al. Front Plant Sci. 2020 Jul 3;11:974. doi: 10.3389/fpls.2020.00974. eCollection 2020. Front Plant Sci. 2020. PMID: 32719701 Free PMC article.
Ole e 1 protein is involved in olive fertilization mechanisms controlling pollen tube development. ...Ole e 1 protein was collected using a Cyclone Sampler and processed with the ELISA methodology. ...
Ole e 1 protein is involved in olive fertilization mechanisms controlling pollen tube development. ...Ole e 1 pr …
901 results